Comparing effectiveness of drugs for rheumatoid arthritis in Saudi Arabia
Comparative Effectiveness of Different Drugs Used to Treat Patients in Rheumatoid Arthritis Saudi Database (RASD) The Primary Objective of This Study is to Compare the Effectiveness of Different Biological Disease Modifying Antirheumatic Drugs (bDMARDs) and Targeted Synthetic (tsDMARDs) Using DAS-28-CRP and CDAI Scores.
This study is trying to see which medications work best for people with rheumatoid arthritis in Saudi Arabia by comparing different treatments and their effects on patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 800 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Umm Al-Qura University Academic / other |
| Drugs / interventions | methotrexate |
| Locations | 1 site (Jeddah, Mecca Region) |
| Trial ID | NCT06417138 on ClinicalTrials.gov |
What this trial studies
This observational study aims to compare the effectiveness of different biological and targeted synthetic Disease Modifying Antirheumatic Drugs (bDMARDs and tsDMARDs) in treating rheumatoid arthritis patients in Saudi Arabia. Utilizing the Rheumatoid Arthritis Saudi Database (RASD), the study will assess treatment outcomes using the Disease Activity Score - 28 joints - C-Reactive Protein (DAS-28-CRP) and Clinical Disease Activity Index (CDAI) scores. The goal is to identify which drug provides the best outcomes for patients with rheumatoid arthritis in this specific population.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and above who meet the American College of Rheumatology classification criteria for rheumatoid arthritis.
Not a fit: Patients who do not meet the inclusion criteria or cannot recall the exact date of starting their medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies for rheumatoid arthritis patients in Saudi Arabia.
How similar studies have performed: While registries have been successful in other regions, this specific comparative effectiveness approach in the Middle East is relatively novel and underexplored.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All those patients who are age of 18 years and above and * meeting 2010 American College of Rheumatology classification criteria for rheumatoid arthritis. * Both male and female gender will be included. * There should be minimum of 12 months follow up with at least 3 documented visits of these patients to health care facilities. Exclusion Criteria: * Any patient who did not meet the inclusion criteria will be excluded from the study. * Any patient who cannot recall the exact date of starting his drugs will be excluded during data analysis.
Where this trial is running
Jeddah, Mecca Region
- International medical center — Jeddah, Mecca Region, Saudi Arabia (Recruiting)
Study contacts
- Principal investigator: Hani Almoallim, Professor — Umm Al-Qura University
- Study coordinator: Hani Almoallim, Professor of Rheumatology
- Email: hmmoallim@uqu.edu.sa
- Phone: 00966+505703935
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.